HOME NEWS EARNINGS RESULTS PICKS STRATEGY BLOG CONTACT SUBSCRIBE LOGIN SUBSCRIBE JOIN FREE
LOADING
Price Investing Group
← Back to Research Watchlist
NRIX
Nurix Therapeutics Inc
Healthcare Biotechnology · California, USA · Reports in usd
Market Cap: $2.47B
Market Cap
$2.47B
Enterprise Val
$1.98B
P/E Ratio
-8.35
P/B Ratio
5.13
Trailing PEG (1Y)
-0.47
As Of
Jul 1, 2026

Overview & Key Metrics

Reporting period: Feb 28, 2026 · Q1 2026
Book Value$480.9M
Gross Margin100.00%
Profit Margin100.00%
Return on Equity-64.21%
Return on Assets-48.44%
Current Ratio6.01
Debt/Equity0.12
LT Debt/Equity0.12
Revenue Per Share0.06

Income Statement

Feb 28, 2026
Revenue$6.3M
Cost of Revenue$0.00
Gross Profit$6.3M
R&D$84.1M
SG&A$14.6M
Operating Expenses$98.7M
Operating Income-$92.5M
Interest Expense$0.00
Tax Expense$0.00
Net Income-$87.2M
EPS (Basic)$-0.79
EPS (Diluted)$-0.79
EBIT-$87.2M
EBITDA-$83.4M
Consolidated Income-$87.2M
Non-Controlling Interests$0.00

Balance Sheet

Feb 28, 2026
Cash & Equivalents$72.2M
Accounts Receivable$0.00
Inventory$0.00
Current Assets$554.4M
LT Investments$0.00
Property, Plant & Equipment$73.4M
Intangibles$0.00
Non-Current Assets$81.7M
Total Assets$636.1M
Accounts Payable$10.3M
Current Debt$3.2M
Current Liabilities$92.2M
LT Debt$55.5M
Non-Current Liabilities$63.0M
Total Liabilities$155.2M
Total Debt$58.7M
Retained Earnings-$1.09B
Shareholder Equity$480.9M
Shares Outstanding102,843,012

Cash Flow Statement

Feb 28, 2026
Operating Cash Flow-$71.9M
Investing Cash Flow-$123.8M
Financing Cash Flow$20.0M
CapEx-$1.0M
Free Cash Flow-$73.0M
Depreciation & Amort.$3.8M
Stock-Based Comp$9.4M
Acquisitions / Disposals$0.00
Investment Activity-$122.8M
Debt Issued/Repaid$0.00
Equity Issued/Repaid$20.0M
Dividends Paid$0.00
Net Change in Cash-$175.8M
Data cached · Meta cache · Daily cache · Statements cache · TTL 24h